OSCR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.12B

+30.55%

-0.921

+48.61%

3.20B

+4.89%

0.682

-25.82%

3.20B

+11.77%

-0.150

-83.15%

Estimates Revision

The market is revising Downward the revenue expectations for Oscar Health, Inc. (OSCR) for FY2025, with the revenue forecasts being adjusted by -0.16% over the past three months. During the same period, the stock price has changed by -13.68%.

Revenue Estimates for FY2025

Revise Downward

-0.16%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-13.68%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast OSCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSCR is 16.06 USD with a low forecast of 11.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

3 Sell

Moderate Sell

Current: 0.000

Low

11.00

Averages

16.06

High

25.00

Current: 0.000

Low

11.00

Averages

16.06

High

25.00

UBS

Sell -> Neutral

upgrade

$12 -> $17

2026-01-09

New

Reason

UBS

Price Target

$12 -> $17

2026-01-09

New

upgrade

Sell -> Neutral

Reason

UBS upgraded Oscar Health to Neutral from Sell with a price target of $17, up from $12. The firm believes that despite the expiration of the enhanced subsidies, Oscar's enrollment in the exchanges are holding up better than feared. UBS says the shares are fairly priced at this level.

Barclays

Andrew Mok

Underweight -> Equal Weight

upgrade

$13 -> $18

2026-01-05

New

Reason

Barclays

Andrew Mok

Price Target

$13 -> $18

2026-01-05

New

upgrade

Underweight -> Equal Weight

Reason

Barclays analyst Andrew Mok upgraded Oscar Health to Equal Weight from Underweight with a price target of $18, up from $13. The firm sees managed care stocks benefiting in 2026 from the prospects of margin expansion and rotation away from artificial intelligence-related stocks toward "de-rated underperformers." Oscar is priced attractively as the market is currently over-discounting the negative outcomes from expiring subsidies, the analyst tells investors in a research note.

Jefferies

downgrade

$12

2025-12-22

Reason

Jefferies

Price Target

$12

2025-12-22

downgrade

Reason

Prospects for an Enhanced Advance Premium Tax Credit extension have diminished, with early Idaho open enrollment period enrollment up 3% year over year but offset by expected non-effectuation, higher voluntary disenrollment, and increased buy-down into bronze plans, Jefferies tells investors in a research note. In Georgia, Kaiser's pause on new enrollment heightens SEP-related medical loss ratio risk for Oscar Health, which is positioned with the first- and second-lowest-cost Silver plans in the state's four most populous counties, the firm says. Jefferies has an Underperform rating and $12 price target on Oscar Health shares.

Stephens

Equal Weight

initiated

$17

2025-12-10

Reason

Stephens

Price Target

$17

2025-12-10

initiated

Equal Weight

Reason

Stephens initiated coverage of Oscar Health with an Equal Weight rating and $17 price target. The firm believes the company's "pure-play focus" to the Affordable Care Act exchanges can be viewed as a "two-way street." The policies that drove Oscar towards profitability are also driving near-term uncertainty to its long-term growth trajectory, the analyst tells investors in a research note.

Piper Sandler

Neutral -> Overweight

upgrade

$13 -> $25

2025-11-25

Reason

Piper Sandler

Price Target

$13 -> $25

2025-11-25

upgrade

Neutral -> Overweight

Reason

Piper Sandler upgraded Oscar Health to Overweight from Neutral with a price target of $25, up from $13.

Piper Sandler

Jessica Tassan

Neutral -> Overweight

upgrade

$13 -> $25

2025-11-25

Reason

Piper Sandler

Jessica Tassan

Price Target

$13 -> $25

2025-11-25

upgrade

Neutral -> Overweight

Reason

As previously reported, Piper Sandler analyst Jessica Tassan upgraded Oscar Health to Overweight from Neutral with a price target of $25, up from $13. Following a deep dive into benefit design, pricing and broker strategy in Miami-Dade, Oscar's largest county, the firm believes Oscar can concurrently grow share and profitability in a scenario where E-APTCs expire at the end of calendar 2025. The firm considers calendar year 2027 adjusted EBITDA of $404M to be "the floor," the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Oscar Health Inc (OSCR.N) is -27.44, compared to its 5-year average forward P/E of 24.75. For a more detailed relative valuation and DCF analysis to assess Oscar Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

24.75

Current PE

-27.44

Overvalued PE

89.18

Undervalued PE

-39.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-29.26

Current EV/EBITDA

-728.67

Overvalued EV/EBITDA

114.46

Undervalued EV/EBITDA

-172.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.50

Current PS

0.31

Overvalued PS

1.00

Undervalued PS

-0.01

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

OSCR News & Events

Events Timeline

No data

News

7.0

16:04 PMYahoo Finance

Oscar Health (OSCR) Enrollment Exceeds Expectations in Health Insurance Exchanges

9.5

03:03 AMBenzinga

Oscar Health Inc. Surges 6.69% Following ACA Subsidy Extension

8.0

01-05NASDAQ.COM

Zeta Global (ZETA) Options Volume Hits 38,288 Contracts, 68.2% of Average Daily Volume

People Also Watch

Frequently Asked Questions

What is Oscar Health Inc (OSCR) stock price today?

The current price of OSCR is 17.73 USD — it has increased 4.91 % in the last trading day.

What is Oscar Health Inc (OSCR)'s business?

Oscar Health, Inc. is a healthcare technology company built around a full stack technology platform. The Company's offerings include its insurance business and +Oscar Platform. Its health plans are offered in the individual market. The individual market primarily consists of policies purchased by individuals and families through health insurance marketplaces, established by the ACA and operated by the federal government, as well as other marketplaces operated by individual states. Individuals and families may also purchase policies in the individual market off-exchange. Employees whose employers have chosen to offer an Individual Coverage Health Reimbursement Arrangement (ICHRA) are also able to purchase its health plans. It offers health plans in the individual market under the five metal plan categories defined by the ACA: Catastrophic, Bronze, Silver, Gold, and Platinum. Through the +Oscar platform, the Company deploys its technology to help others throughout the healthcare system.

What is the price predicton of OSCR Stock?

What is Oscar Health Inc (OSCR)'s revenue for the last quarter?

Oscar Health Inc revenue for the last quarter amounts to 2.99B USD, increased 23.21 % YoY.

What is Oscar Health Inc (OSCR)'s earnings per share (EPS) for the last quarter?

Oscar Health Inc. EPS for the last quarter amounts to -0.53 USD, increased 140.91 % YoY.

What changes have occurred in the market's expectations for Oscar Health Inc (OSCR)'s fundamentals?

How many employees does Oscar Health Inc (OSCR). have?

Oscar Health Inc (OSCR) has 2400 emplpoyees as of January 09 2026.

What is Oscar Health Inc (OSCR) market cap?

Today OSCR has the market capitalization of 4.36B USD.